RecruitingPhase 3ACTRN12613000495729

Dexmeditomedine for mitral valve replacement

dexmeditomedine for heart rate control during mitral valve replacement for mitral stenosis a randomised controlled double blind study


Sponsor

south valley university -Qena university hospital

Enrollment

70 participants

Start Date

Nov 5, 2011

Study Type

Interventional

Conditions

Summary

testing the efficacy and safety of dexmeditomedine in controlling heart rate in patients with tight mitral stenosis subjected to mitral valve replacement during the prebypass period


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 60 Yearss

Plain Language Summary

Simplified for easier understanding

This study is testing a medication called dexmedetomidine to see if it can safely and effectively control heart rate in patients with severe mitral stenosis — a condition where the heart's mitral valve has narrowed significantly — before they undergo valve replacement surgery. Controlling heart rate during this time is important because it helps the heart pump blood more efficiently before the surgeon repairs the valve. You may be eligible if: - You are between 18 and 60 years old - You have been diagnosed with tight (severe) mitral stenosis with a valve area less than 1 cm - You are scheduled for mitral valve replacement surgery - You are classified as low-to-moderate surgical risk (ASA I or II) You may NOT be eligible if: - You are under 18 or over 60 years old - Your mitral valve area is greater than 1 cm - You have kidney or liver problems - You take heart medications that affect heart rate Talk to your doctor about whether this trial might be right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

70 patients scheduled for mitral valve replacement divided equally into two groups were studied in this randomized controlled double blind study ; Group D : received (after induction of anesthesia) de

70 patients scheduled for mitral valve replacement divided equally into two groups were studied in this randomized controlled double blind study ; Group D : received (after induction of anesthesia) dexmeditomedine 1ug/kg bolus dose over 10 minutes followed by an infusion of 0.5 ug/kg/h till the start of cardiopulmonary bypass. Group F: received saline bolus ( after induction of anesthesia ) and infusion of saline till the start of cardiopulmonary bypass instead of dexmeditomedine .Anesthetic management for both groups was the same.


Locations(1)

Qena - upper Egypt, Egypt

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12613000495729